EVFM - Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier

• Evofem Biosciences focuses on women's sexual and reproductive health and recently developed Phexxi, a non-hormonal female contraceptive.
• CEO Saundra Pelletier discusses investing implications of the Roe v Wade reversal.
• Breaking down EVFM’s strong growth rating despite poor profitability and momentum scores according to Seeking Alpha’s Quant system.

The interview was recorded on June 16th, 2022 (Roe v Wade was overturned on June 24th, 2022).

Evofem Biosciences ( NASDAQ: EVFM ) is a pharmaceutical company that developed Phexxi ,a non-hormonal female contraceptive . EVFM’s stock price increased two-fold following the reversal of Roe v Wade. CEO Saundra Pelletier joined us to discuss the financial and ethical implications of the Roe v Wade reversal. We also break down EVFM’s very strong growth rating, despite its poor profitability and momentum scores according to Seeking Alpha’s Quant system . Plans to cash-break-even by 2023 and profitability by 2024. Opportunities for global licensing made possible by the FDA’s recent extension of Phexxi’s shelf-life.

For further details see: